MorphoSys AG American Depositary Shares - MOR STOCK NEWS

MorphoSys AG (FSE:MOR; NASDAQ:MOR) reported Q1 2021 financial results, revealing total revenues of €47.2 million, down 81% year-over-year. Key highlights include Monjuvi U.S. net product sales of €12.9 million (US$ 15.5 million) and Tremfya royalties of €11.6 million. Operating loss reached €29.6 million compared to a profit of €203.5 million in Q1 2020, with a consolidated net loss of €41.6 million. The company reaffirmed its 2021 revenue guidance of €150 to €200 million, focusing on Monjuvi's launch and ongoing clinical studies. A conference call is scheduled for May 6, 2021.

MorphoSys AG will release its first quarter 2021 financial results on May 5, 2021, at 10:00 PM CEST. A conference call will be held the next day, May 6, 2021, at 2:00 PM CEST, where the Management Board will present the results and outlook. The call will feature CEO Jean-Paul Kress and other board members, followed by a Q&A session. A live webcast will be available on the company's website, and a replay will be accessible afterward. MorphoSys focuses on innovative therapies for cancer and autoimmune diseases.

Incyte and MorphoSys have initiated the Phase 3 inMIND study, with the first patient dosed, to evaluate the efficacy and safety of tafasitamab combined with lenalidomide and rituximab in treating relapsed or refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL). The study aims to enroll over 600 patients, targeting improved progression-free survival. Despite advancements in treatment, a significant medical need remains for FL and MZL therapies, as these conditions constitute a large segment of non-Hodgkin lymphoma cases.

MorphoSys AG (FSE:MOR; NASDAQ:MOR) and Incyte (NASDAQ:INCY) have announced the commencement of the Phase 3 inMIND study, with the first patient dosed to evaluate the efficacy and safety of tafasitamab in combination with lenalidomide and rituximab for patients with relapsed or refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL). The study targets over 600 adults and focuses on improving treatment outcomes for these slow-growing B-cell non-Hodgkin lymphomas, addressing a significant medical need in this patient population.

MorphoSys AG (FSE:MOR) reported substantial growth in its financial results for 2020, achieving revenues of €327.7 million, up from €71.8 million in 2019. The company’s EBIT improved to €27.4 million, reversing a loss of €107.9 million in the previous year. Monjuvi product sales totaled €18.5 million since its U.S. launch in August 2020, while royalties from Tremfya reached €42.5 million. MorphoSys ended 2020 with a robust liquidity position of €1.24 billion, setting a strong foundation for 2021’s projected revenue of €150 to €200 million.

MorphoSys AG (FSE:MOR; NASDAQ:MOR) will announce its financial results for 2020 on March 15, 2021, at 10:00 pm CET. A conference call hosted by the management team to discuss these results, as well as an outlook for 2021, will take place on March 16, 2021, at 2:00 pm CET. Key presenters include CEO Jean-Paul Kress and other executives. A live webcast will be available on the company's website, and a replay will follow shortly after the event.

MorphoSys focuses on innovative therapies for cancer and autoimmune diseases, having developed multiple candidates, including its FDA-approved product, Monjuvi.

MorphoSys AG announced that its partner GlaxoSmithKline reported preliminary results from the OSCAR study on otilimab for severe COVID-19. The findings indicate a significant clinical benefit for high-risk patients, prompting GSK to expand the study cohort. This expansion triggers €16 million in milestone payments to MorphoSys. Otilimab, developed for severe pulmonary COVID-19 and rheumatoid arthritis, has been evaluated in over 800 participants across various global sites. The full analysis will be published in a pre-print publication.

MorphoSys AG has announced preliminary results for the fiscal year 2020, reporting revenues of €327.7 million, exceeding its previous guidance of €317 to 327 million. This includes €18.5 million from Monjuvi^(R) sales and €42.5 million in royalties from Tremfya^(R). The expected EBIT stands at €27.4 million, significantly above the guidance range of €10 to 20 million. R&D expenses are projected at €141.4 million, slightly over the guided range. Full financial results will be disclosed on March 15, 2021.

MorphoSys and I-Mab announced the dosing of the first patient in a phase 1 trial for MOR210/TJ210, targeting advanced solid tumors. This monoclonal antibody inhibits C5aR1, potentially enhancing anti-tumor immunity. Preclinical data indicated a favorable safety profile and promising anti-tumor effects, with the study designed to evaluate safety, tolerability, and pharmacokinetics. A milestone payment of $1.5 million will be received by MorphoSys from I-Mab. The ongoing study may lead to future combination therapies with immune checkpoint inhibitors.